Close

Anti-CEA (MFZ) h(41BB-CD3ζ) CAR, pMMLV (CAR-MV-01LX364)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Recombinant Moloney murine leukemia virus (MMLV) retroviral vectors serve as efficient viral vector tools for introducing genes permanently into a wide variety of dividing cells, and provide an alternative to modify primary T cells. Creative biolabs has developed retroviral CAR vector pMMLV CEA (MFZ) h(BBζ), which is constructed for the engineering of T cells to target human CEA. The T cells are genetically modified through transduction with a retroviral vector expressing scFv of anti-CEA antibody linked to CD137 (4-1BB) and CD3-zeta signaling domains. And the vector product was designed for the treatment of Pancreatic cancer.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • CEA
  • Targeting Cell Type
  • T cell
  • Targeting Diseases
  • Pancreatic cancer
  • Generation
  • Second
  • Vector Name
  • pMMLV
  • Vector Length
  • ~6kb
  • Vector Type
  • Recombinant Moloney murine leukemia virus (MMLV) retroviral vector
  • Receptor Construction
  • scFv-41BB-CD3ζ
  • Discription of Signaling Cassetes
  • 41BB
    CD137 (also known as 4-1BB) is a surface co-stimulatory glycoprotein originally described as present on activated T lymphocytes, which belongs to the tumor necrosis factor (TNF) receptor superfamily. It is expressed mainly on activated CD4+ and CD8+ T cells, and binds to a high-affinity ligand (4-1BBL) expressed on several antigen-presenting cells such as macrophages and activated B cells. On the basis of preclinical observation, this molecule can promote the persistence of antigen-specific and antigennonspecific chimeric antigen receptor T-cells to significantly increases antitumor activity.
    CD3ζ
    CD3ζ, also known as T-cell receptor zeta, which together with T-cell receptor and CD3γ, δ, ε chain, forms the TCR-CD3 complex. ζ was expressed independently from the complex. The zeta chain plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways. CD3-zeta, which contains 3 ITAMs, is the most commonly used endodomain component of CARs. It transmits an activation signal to the T cell after antigen is bound. CD3-zeta may not provide a fully competent activation signal and additional co-stimulatory signaling is needed. For example, chimeric 4-1BB and OX40 can be used with CD3-zeta to transmit a proliferative/survival signal, or all three can be used together.

Target

  • Clone
  • MFZ
  • Host
  • human
  • Target Species
  • Human
  • Gene Name
  • CEA
  • Synonyms
  • CEA; CD66e;

Customize Your CAR Products

Cannot find the desired product? Don't worry, just try our online CAR and CAR cell customizing system, which offers full options to meet all unique needs, including but not limited to conventional or unconventional CAR constructs, as well as a variety of vectors and cells. The customization process can be completed with just a few simple clicks, please feel free to try it out.
CAR and CAR Cell Customizing System
  • Published Data
Complete CAR data FCM

Fig.1 Both CD4 and CD8 T cells were modified with the CAR and used for adoptive transfer in this study

CAR Construction : MFZ scFv-28ζ Latest CAR Construction

Fig.1 Both CD4 and CD8 T cells were modified with the CAR and used for adoptive transfer in this study

CAR expression was monitored by flow cytometry using a phycoerythrin-labeled anti-mouse IgG1 antibody and an allophycocyanin-conjugated antibody directed against CD4 and CD8.

Chmielewski, M., Hahn, O., Rappl, G., Nowak, M., Schmidt–Wolf, I. H., Hombach, A. A., & Abken, H. (2012). T cells that target carcinoembryonic antigen eradicate orthotopic pancreatic carcinomas without inducing autoimmune colitis in mice. Gastroenterology, 143(4), 1095-1107.

Complete CAR data Cyt

Fig.2 T cells with anti-CEA CAR were coincubated at the indicated effector-to-tumor cell ratios with Panc02 cells with or without CEA expression for 48 hours.

CAR Construction : MFZ scFv-28ζ Latest CAR Construction

Fig.2 T cells with anti-CEA CAR were coincubated at the indicated effector-to-tumor cell ratios with Panc02 cells with or without CEA expression for 48 hours.

Cytotoxicity was assessed by an XTT-based viability assay. All measurements were performed in triplicate.

Chmielewski, M., Hahn, O., Rappl, G., Nowak, M., Schmidt–Wolf, I. H., Hombach, A. A., & Abken, H. (2012). T cells that target carcinoembryonic antigen eradicate orthotopic pancreatic carcinomas without inducing autoimmune colitis in mice. Gastroenterology, 143(4), 1095-1107.

Complete CAR data FCM

Fig.3 Lung epithelia cells were isolated from the lung of CEAtg mice. Cells were stained for CEA and flow sorted before use in the study.

CAR Construction : MFZ scFv-28ζ Latest CAR Construction

Fig.3 Lung epithelia cells were isolated from the lung of CEAtg mice. Cells were stained for CEA and flow sorted before use in the study.

Mouse CEA Panc02 pancreatic carcinoma cells and fibrosarcoma CEA C15A3 cells were used for comparison.

Chmielewski, M., Hahn, O., Rappl, G., Nowak, M., Schmidt–Wolf, I. H., Hombach, A. A., & Abken, H. (2012). T cells that target carcinoembryonic antigen eradicate orthotopic pancreatic carcinomas without inducing autoimmune colitis in mice. Gastroenterology, 143(4), 1095-1107.

Complete CAR data IHC

Fig.4 CEA Panc02 pancreatic carcinoma cells were inoculated into the pancreas of CEAtg mice. After 3 weeks, the tumor tissue, as well as the healthy pancreas (without tumor), were recorded by H&E and CEA staining.

CAR Construction : MFZ scFv-28ζ Latest CAR Construction

Fig.4 CEA Panc02 pancreatic carcinoma cells were inoculated into the pancreas of CEAtg mice. After 3 weeks, the tumor tissue, as well as the healthy pancreas (without tumor), were recorded by H&E and CEA staining.

The CEAtg mouse expressed CEA in transplanted CEA+ Panc02 pancreatic carcinoma as well as in healthy tissues.

Chmielewski, M., Hahn, O., Rappl, G., Nowak, M., Schmidt–Wolf, I. H., Hombach, A. A., & Abken, H. (2012). T cells that target carcinoembryonic antigen eradicate orthotopic pancreatic carcinomas without inducing autoimmune colitis in mice. Gastroenterology, 143(4), 1095-1107.

Complete CAR data FuncS

Fig.5 Regression of transplanted pancreas carcinoma upon adoptive therapy with anti-CEA CAR T cells.

CAR Construction : MFZ scFv-28ζ Latest CAR Construction

Fig.5 Regression of transplanted pancreas carcinoma upon adoptive therapy with anti-CEA CAR T cells.

CBLuc-marked Panc02 tumor cells and GLuc-marked T cells were recorded by bioluminescence imaging in the same mouse at the indicated days before and after T-cell transfer.

Chmielewski, M., Hahn, O., Rappl, G., Nowak, M., Schmidt–Wolf, I. H., Hombach, A. A., & Abken, H. (2012). T cells that target carcinoembryonic antigen eradicate orthotopic pancreatic carcinomas without inducing autoimmune colitis in mice. Gastroenterology, 143(4), 1095-1107.

More Published Data More Published Data

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-CEA (MFZ) h(41BB-CD3ζ) CAR, pMMLV (CAR-MV-01LX364). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.